Rovalpituzumab  (Synonyms: SC-0001)

Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC)^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

DLL3

Rovalpituzumab Tesirine can be used for the study of SCLC with DLL3 expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

10683  [NCBI]

Q9NYJ7

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.02 kDa

1613313-01-1

Liquid

Colorless to light yellow

[Rovalpituzumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Delta-like protein 3/DLL3 Protein, Human (Biotinylated, HEK293, His, HY-P78115) can bind Rovalpituzumab. The EC₅₀ for this effect is 3.245 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ U118MG cells with Rovalpituzumab (HY-P99043, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Bilal H Lashari, et al. Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate. Drugs R D. 2018 Dec;18(4):255-258.  [Content Brief]